Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules

European Journal of Biochemistry

Volumn 269, Issue 21, 2002, Pages 5103-5111

  Sluis Cremer, Nicolas ^a   Tachedjian, Gilda ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

Author keywords

Inhibiting protein protein interactions; Integrase; Oligomeric structure; Protease; Reverse transcriptase

Indexed keywords

2',5' BIS[(TERT BUTYLDIMETHYLSILYL) BETA DEXTRO RIBOFURANOSYL] 3' SPIRO 5'' (4'' AMINO 1',2' OXATHIOLE 2',2' DIOXIDE)THYMINE; ALDEHYDE DERIVATIVE; DELAVIRDINE; EFAVIRENZ; ENZYME INHIBITOR; INTEGRASE; N (4 TERT BUTYLBENZOYL) 2 HYDROXY 1 NAPHTHALDEHYDE HYDRAZONE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; OLIGOMER; PEPTIDE; PROTEIN INHIBITOR; PROTEINASE; RNA DIRECTED DNA POLYMERASE; THYMINE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS ENZYME;

ANTIVIRAL ACTIVITY; CONFORMATIONAL TRANSITION; DIMERIZATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME STRUCTURE; FLUORESCENCE ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW;

ANTI-HIV AGENTS; DIMERIZATION; DRUG DESIGN; ENZYME INHIBITORS; HIV INTEGRASE; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; MODELS, MOLECULAR; PEPTIDES; PROTEIN CONFORMATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0036428535     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-1033.2002.03216.x     Document Type: Review

References (70)

1. Barre-Sinoussi, F., Chermann, J.C., Rey, F., Nugeyre, M.T., Chamaret, S., Gruest, J., Dauguet, C., Axler-Blin, C., Brun-Vezinet, F., Rouzioux, C., Rozembaum, W. & Montagnier, L. (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immunodeficiency syndrome (AIDS). Science 220, 868-871.
2. Popovic, M., Sarngadharan, M.G., Read, E. & Gallo, R.C. (1984) Detection, isolation and continuous production of cytoplasmic retrovirus (HTLV-III) from patient with AIDS and pre-AIDS. Science 224, 497-500.
3. Miller, M.D. & Hazuda, D.J. (2001) New antiretroviral agents: Looking beyond protease and reverse transcriptase. Curr. Opin. Microbiol. 4, 535-539.
4. Condra, J.H., Miller, M.D., Hazuda, D.J. & Emini, E.A. (2002) Potential new therapies for the treatment of HIV-1 infection. Annu. Rev. Med. 53, 541-555.
5. Heldin, C.-H. (1995) Dimerization of cell surface receptors in signal transduction. Cell 80, 213-223.
6. Gibson, W. (1996) Structure and assembly of the virion. Intervirology 39, 389-400.
7. Zutshi, R., Brickner, M. & Chmielewski, J. (1998) Inhibiting the assembly of protein-protein interfaces. Curr. Opin. Chem. Biol. 2, 62-66.
8. Liuzzi, M., Deziel, R., Moss, N., Beaulieu, P., Bonneau, A.-M., Bousquet, C., Chafouleas, J.G., Garneau, M., Jaramillo, J., Krogsrud, R.L. et al. (1994) A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo. Nature 372, 695-698.
9. Tilley, J.W., Chen, L., Fry, D.C., Emerson, S.D., Powers, G.D., Biondi, D., Varnell, T., Trilles, R., Guthrie, R., Mennoma, F., Kaplan, G., LeMahieu, R.A., Carson, M., Han, R.-J., Liu, C.-M., Palmermo, R. & Ju, G. (1997) Identification of a small molecule inhibitor of the IL-2/IL-2Ra receptor interaction which binds to IL-2. J. Am. Chem. Soc. 119, 7589-7590.
10. Judice, K. (1997) Small molecule inhibitors of human growth hormone/receptor binding. FASEB J. 11, A839.
11. Babe, L.M., Pichuantes, S. & Craik, C.S. (1991) Inhibition of HIV protease activity by heterodimer formation. Biochemistry 30, 106-111.
12. Restle, T., Mudie;ller, B. & Goody, R.S. (1990) Dimerization of human immunodeficiency virus type 1 reverse transcriptase: A target for chemotherapeutic intervention. J. Biol. Chem. 265, 8986-8988.
13. Esposito, D. & Craigie, R. (1999) HIV integrase structure and function. Adv. Virus Res. 52, 319-333.
14. Wlodawer, A., Miller, M., Jaskólski, M., Sathyanarayana, B.K., Baldwin, E., Weber, I.T., Selk, L.M., Clawson, L., Schneider, J. & Kent, S.B.H. (1989) Conserved folding in retroviral proteases: Crystal structure of a synthetic HIV-1 protease. Science 245, 616-621.
15. Todd, M.J., Semo, N. & Freire, E. (1998) The structural stability of the HIV-1 protease. J. Mol. Biol. 283, 475-488.
16. Zhang, Z.-Y., Poorman, R.A., Maggiora, L.L., Heinrikson, R.L. & Keacute;zdy, F.J. (1991) Dissociative inhibition of dimeric enzymes. J. Biol. Chem. 266, 15591-15594.
17. Schramm, H.J., Nakashima, H., Schramm, W., Wakayama, H. & Yamamoto, N. (1991) HIV-1 reproduction is inhibited by peptides derived from the N- and C-termini of HIV-1 protease. Biochem. Biophys. Res. Commun. 179, 847-851.
18. Bab́, L.M., Rose, J. & Craik, C.S. (1992) Synthetic "interface" peptides alter dimeric assembly of the HIV 1 and HIV 2 proteases. Protein Sci. 1, 1244-1253.
19. Franciskovich, J., Houseman, K., Mueller, R. & Chmielewski, J. (1993) A systematic evaluation of the inhibition of HIV-1 protease by its C- and N-terminal peptides. Bioorg. Med. Chem. Lett. 3, 765-768.
20. Schramm, H.J., Boetzel, J., Büttner, J., Fritsche, E., Göhring, W., Jaeger, E., König, S., Thumfart, O., Wenger, T., Nagel, N.E. & Schramm, W. (1996) The inhibition of human immunodeficiency virus proteases by "interface peptides". Antiviral Res. 30, 155-170.
21. Schramm, H.J., de Rosny, E., Reboud-Ravaux, M., Büttner, J., Dick, A. & Schramm, W. (1999) Lipopeptides as dimerization inhibitors of HIV-1 protease. Biol. Chem. 380, 593-596.
22. Zutshi, R., Franciskovich, J., Shultz, M., Schweitzer, B., Bishop, P., Wilson, M. & Chmielewski, J. (1997) Targeting the dimerization interface of HIV-1 protease: Inhibition with the cross-linked interfacial peptides. J. Am. Chem. Soc. 119, 4841-4845.
23. Bouras, A., Boggetto, N., Benatalah, Z., de Rosny, E., Sicsic, S. & Reboud-Ravaux, M. (1999) Design, synthesis, and evaluation of conformationally constrained tongs, new inhibitors of HIV-1 protease dimerization. J. Med. Chem. 42, 957-962.
24. Song, M., Rajesh, S., Hayashi, Y. & Kiso, Y. (2001) Design and synthesis of new inhibitors of HIV-1 protease dimerization with conformationally constrained templates. Bioorg. Med. Chem. Lett. 11 2465-2468.
25. Zutshi, R. & Chmielewski, J. (2000) Targeting the dimerization interface for irreversible inhibition of HIV-1 protease. Bioorg. Med. Chem. Lett. 10, 1901-1903.
26. Uhlíková, T., Konvalinka, J., Pichová, Soucek, M., Kräusslich, H.-G. & Vondrásek, J. (1996) A modular approach to HIV-1 proteinase inhibitor design. Biochem. Biophys. Res. Commun. 222, 38-43.
27. Park, S.-H. & Raines, R.T. (2000) Genetic selection for dissociative inhibitors of designated protein-protein interactions. Nat. Biotechnol. 18, 847-851.
28. Quéré, L., Wenger, T. & Schramm, H.J. (1996) Triterpenes as potential dimerization inhibitors of HIV-1 protease. Biochem. Biophys. Res. Commun. 227, 484-488.
29. Fan, X., Flentke, G.R. & Rich, D.H. (1998) Inhibition of HIV-1 protease by a subunit of didemnaketal A. J. Am. Chem. Soc. 120, 8893-8894.
30. Telesnitsky, A. & Goff, S. (1997) Reverse transcriptase and the generation of retroviral DNA. Retroviruses (Coffin, J., Hughes, S. & Varmus H., eds), pp. 121-160. Cold Spring Harbor Laboratory Press, Plainview, NY.
31. Di Marzo Veronese, F., Copeland, T.D., DeVico, A.L., Rahman, R., Oroszlan, S., Gallo, R.C. & Sarngadharan, M.G. (1986) Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science 231, 1289-1291.
32. Hsiou, Y., Ding, J., Das, K., Clark, A.D. Jr, Hughes, S.H. & Arnold, E. (1996) Structure of unliganded HIV-1 reverse tran-scriptase at 2.7 Å resolution: Implications of conformational changes for polymerization and inhibition mechanisms. Structure 4, 853-860.
33. Wang, J., Smerdon, S.J., Jager, J., Kohlstaedt, L.A., Rice, P.A., Friedman, J.M. & Steitz, T.A. (1994) Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse tran-scriptase heterodimer. Proc. Natl Acad. Sci. USA 91, 7242-7246.
34. Rodgers, D.W., Gamblin, S.J., Harris, B.A., Ray, S., Culp, J.S., Hellmig, B., Woolf, D.J., Debouck, C. & Harrison, S.C. (1995) The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA 92, 1222-1226.
35. Kohlsteaedt, L.A., Wang, J., Friedman, J.M., Rice, P.A. & Steitz, T.A. (1992) Crystal structure of 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256, 1783-1790.
36. Ren, J., Esnouf, R., Garman, E., Somers, D., Ross, C., Kirby, I., Keeling, J., Darby, G., Jones, Y., Stuart, D. & Stammers, D. (1995) High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol. 2, 293-302.
37. Das, K., Ding, J., Hsiou, Y., Clark, A.D. Jr, Moereels, H., Koy-mans, L., Andries, K., Pauwels, R., Janssen, P.A., Boyer, P.L., Clark, P., Smith, R.H. Jr, Kroeger Smith, M.B., Michejda, C.J., Hughes, S.H. & Arnold, E. (1996) Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J. Mol. Biol. 264, 1085-1100.
38. Jacobo-Molina, A., Ding, J., Nanni, R.G., Clark, A.D. Jr, Lu, X., Tantillo, C., Williams, R.L., Kamer, G., Ferris, A.L., Clark, P., Hizi, A., Huges, S.H. & Arnold, E. (1993) Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Natl Acad. Sci. USA 90, 6320-6324.
39. Sarafianos, S.G., Das, K., Tantillo, C., Clark, A.D. Jr, Ding, J., Whitcomb, J.M., Boyer, P.L., Hughes, S.H. & Arnold, E. (2001) Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA: DNA. EMBO J. 20, 1449-1461.
40. Huang, H., Chopra, R., Verdine, G.L. & Harrison, S.C. (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance. Science 282, 1669-1675.
41. Rodríguez-Barrios, F., Pérez, C., Lobatón, E., Velázquez, S., Chamorro, C., San-Félix, A., Pérez-Pérez, M.J., Camarasa, M.J.,Pelemans, H., Balzarini, J. & Gago, F. (2001) Identification of a putative binding site for [2′,5′-Bis-O-(tert-butyldi-methylsilyl)-β-D-ribofuranosyl]- 3′-spiro-5′-(4′-amino-1′,2′-oxathi-ole-2 ′,2′-dioxide) thymine (TSAO) derivatives at the p51-p66 interface of the HIV-1 reverse transcriptase. J. Med. Chem. 44, 1853-1865.
42. Menéndez-Arias, L., Abraha, A., Quinones-Mateu, M.E., Mas, A., Camarasa, M.J. & Arts, E.J. (2001) Functional characterization of chimeric reverse transcriptases with polypeptide subunits of highly divergent HIV-1 group M and O strains. J. Biol. Chem. 276, 27470-27479.
43. Divita, G., Rittinger, K., Restle, T., Immendorfer, U. & Goody, R.S. (1995) Conformational stability of dimeric HIV-1 and HIV-2 reverse transcriptases. Biochemistry 34, 16337-16346.
44. Sluis-Cremer, N., Dmitrienko, G.I., Balzarini, J., Camarasa, M.J. & Parniak, M.A. (2000) Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[spiro[4′-amino-2′,2′-dioxo-1′,2′-oxathiole- 5′,3′-[2′,5′-bis-O-(tert-butyldimethylsi-lyl)-beta- D-ribofuranosyl]]]-3-ethylthymine. Biochemistry 39, 1427-1433.
45. Divita, G., Restle, T., Goody, R.S., Chermann, J.C. & Baillon, J.G. (1994) Inhibition of human immunodeficiency virus type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain. J. Biol. Chem. 269, 13080-13083.
46. Divita, G., Baillon, J.G., Rittinger, K., Chermann, J.C. & Goody, R.S. (1995) Interface peptides as structure-based human immunodeficiency virus reverse transcriptase inhibitors. J. Biol. Chem. 270, 28642-28646.
47. Morris, M.C., Robert-Hebmann, V., Chaloin, L., Mery, J., Heitz, F., Devaux, C., Goody, R.S. & Divita, G. (1999) A new potent HIV-1 reverse transcriptase inhibitor. A synthetic peptide derived from the interface subunit domains. J. Biol. Chem. 274, 24941-24946.
48. Swanstrom, R. & Wills, J. (1997) Synthesis, assembly, and processing of viral proteins. In Retroviruses (Coffin, J., Hughes, S. & Varmus, H., eds), pp. 263-334. Cold Spring Harbor Laboratory Press, Plainview, NY.
49. Yu Q., Ottmann, M., Pechoux, C., Le Grice, S. & Darlix, J.L. (1998) Mutations in the primer grip of human immunodeficiency virus type 1 reverse transcriptase impair proviral DNA synthesis and virion maturation. J. Virol. 72, 7676-7680.
50. Divita, G., Rittinger, K., Geourjon, C., Deleage, G. & Goody, R.S. (1995) Dimerization kinetics of HIV-1 and HIV-2 reverse transcriptase: A two step process. J. Mol. Biol. 245, 508-521.
51. Morris, M.C., Berducou, C., Mery, J., Heitz, F. & Divita, G. (1999) The thumb domain of the p51-subunit is essential for activation of HIV reverse transcriptase. Biochemistry 38, 15097-15103.
52. Sluis-Cremer, N., Arion, D. & Parniak, M.A. (2002) Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. Mol. Pharmacol. 62, 398-405.
53. Balzarini, J., Pérez-Pérez, M.J., San-Félix, A., Schols, D., Perno, C.F., Vandamme, A.M., Camarasa, M.J. & De Clercq, E. (1992) 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2′-dioxide) pyrimidine (TSAO) nucleoside analogues: Highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc. Natl Acad. Sci. USA 89, 4392-4396.
54. Balzarini, J., Pérez-Pérez, M.J., San-Félix, A., Camarasa, M.J., Bathurst, I.C., Barr, P.J. & De Clercq, E. (1992) Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofurano-syl]- 3′-spiro-5′-(4′-amino-1′,2′-oxathiole-2 ′,2′-dioxide) thymine (TSAO-T). J. Biol. Chem. 267, 11831-11838.
55. Jonckheere, H., Taymans, J.M., Balzarini, J., Velazquez, S., Camarasa, M.J., Desmyter, J., De Clercq, E. & Anne, J. (1994) Resistance of HIV-1 reverse transcriptase against [2′,5′-bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide)] (TSAO) derivatives is determined by the mutation Glu138 fi Lys on the p51 subunit. J. Biol. Chem. 269, 25255-25258.
56. Borkow, G., Fletcher, R.S., Barnard, J., Arion, D., Motakis, D., Dmitrienko, G.I. & Parniak, M.A. (1997) Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthalde-hyde hydrazone. Biochemistry 36, 3179-3185.
57. Arion, D., Sluis-Cremer, N., Min, K.-L., Abram, M.E., Fletcher, R.S. & Parniak, M.A. (2002) Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazones. J. Biol. Chem. 277, 1370-1374.
58. Tachedjian, G., Orlova, M., Sarafianos, S.G., Arnold, E. & Goff, S.P. (2001) Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc. Natl Acad. Sci. USA 98, 7188-7193.
59. Tachedjian, G., Aronson, H.E. & Goff, S.P. (2000) Analysis of mutations and suppressors aWecting interactions between the subunits of the HIV type 1 reverse transcriptase. Proc. Natl Acad. Sci. USA 97, 6334-6339.
60. Esnouf, R.M., Ren, J., Hopkins, A.L., Ross, C.K., Jones, E.Y., Stammers, D.K. & Stuart, D.I. (1997) Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis (heteroaryl) piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc. Natl Acad. Sci. USA 94, 3984-3989.
61. Engelman, A., Mizuuchi, K. & Craigie, R. (1991) HIV-1 DNA integration: Mechanism of viral DNA cleavage and DNA strand transfer. Cell 67, 1211-1221.
62. Asante-Appiah, E. & Skalka, A.M. (1999) HIV-1 integrase: Structural organization, conformational changes, and catalysis. Adv. Virus Res. 52, 351-369.
63. Zheng, R., Jenkins, T.M. & Craigie, R. (1996) Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization and enhances activity. Proc. Natl Acad. Sci. USA 93, 13659-13664.
64. Brown, P. (1997) Integration. In Retroviruses (eds Coffin, S., Hughes, S.H. & Varmus, H.E.), pp. 161-203. Cold Spring Harbor Laboratory Press, Plainview, NY.
65. Cai, M., Zheng, R., CaWrey, R., Clore, M. & Gronenborn, A.M. (1997) Solution structure of N-terminal zinc binding domain of HIV-1 integrase. Nat. Struct. Biol. 4, 567-577.
66. Dyda, F., Hickman, A.B., Jenkins, T.M., Engelman, A., Craigie, R. & Davies, D.R. (1994) Crystal structure of the catalytic domain of HIV-1 integrase: Similarity to other polynucleotidyl trans-ferases. Science 266, 1981-1986.
67. Lodi, P.J., Ernst, J.A., Kuszewski, J., Hickman, A.B., Engelman, A., Craigie, R., Clore, G.M. & Gronenborn, A.M. (1995) Solution structure of the DNA binding domain of HIV-1 integrase. Biochemistry 34, 9826-9833.
68. Chen, J.C.-H., Krucinski, J., Miercke, L.J.W., Finer-Moore, J.S., Tang, A.H., Leavitt, A.D. & Stroud, R.M. (2000) Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: A model for viral DNA binding. Proc. Natl Acad. Sci. USA 97, 8233-8238.
69. Wang, J.-Y., Ling, H., Yang, W. & Craigie, R. (2001) Structure of a two-domain fragment of HIV-1 integrase: Implications for domain organization in the intact protein. EMBO J. 20, 7333-7343.
70. Maroun, R.G., Gayet, S., Benleulmi, M.S., Porumb, H., Zargarian, L., Merad, H., Leh, H., Moucadet, J.-L., Troalen, F. & Fermandjian, S. (2001) Peptide Inhibitors of HIV-1 integrase dissociate the enzyme oligomers. Biochemistry 40, 13840-13848.